Share This Page
Drug Price Trends for REBIF REBIDOSE
✉ Email this page to a colleague
Average Pharmacy Cost for REBIF REBIDOSE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| REBIF REBIDOSE 44 MCG/0.5 ML | 44087-3344-01 | 1848.67278 | ML | 2026-01-03 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for REBIF REBIDOSE
What is REBIF REBIDOSE?
REBIF REBIDOSE (interferon beta-1a, biosimilar) is a long-acting formulation used in multiple sclerosis (MS) therapy. It maintains the same indication as the originator, Avonex, for the treatment of relapsing forms of MS. The biosimilar offers a potentially lower-cost alternative, designed for self-injection once weekly.
Market Position and Competitors
Key Players
- Originator: Avonex (Biogen)
- Biosimilars:
- REBIF REBIDOSE (produced by Mylan)
- Other biosimilars in development or marketed by Biogen's competitors, such as Samsung Bioepis and Sandoz
Market Share Dynamics
- The MS biologics segment is estimated at $25 billion globally in 2022.
- Biosimilars for MS are gaining approval, with REBIF REBIDOSE entering markets with high MS prevalence, like Europe, the U.S., and Japan.
- Market penetration depends on regulatory approvals, pricing strategies, and physician and patient acceptance.
Regulatory Status
- Approved in Europe (EMA, 2021).
- Awaiting or under review in the U.S. (FDA, 2022).
- Market launch timelines vary by region, with initial focus on Europe.
Price Setting and Cost Competition
Pricing of Originator (Avonex)
- U.S. list price: approximately $63,000 per year per patient (price varies by payer discounts).
- European prices: usually lower, around €30,000–€40,000 annually, depending on country.
Biosimilar Pricing Strategies
- Initial biosimilar prices typically at a 15-25% discount relative to the originator.
- For REBIF REBIDOSE:
- Expected launch price: approximately $50,000–$55,000 annually in the U.S.
- European markets: around €25,000–€30,000 annually.
- These prices are influenced by rebate negotiations, basket discounts, and payer contracts.
Cost Impact on Market
- Once launched, biosimilars tend to reduce overall MS biologic expenditure by 20-30%.
- Price erosion accelerates with increased market share, potentially reducing biosimilar prices by as much as 50% within five years of launch.
Market Adoption Potential
Drivers
- Cost incentives for payers and healthcare systems.
- Physician familiarity with biosimilar safety and efficacy.
- Patient preference for injections with similar or improved convenience.
- Policy incentives in regions promoting biosimilar use.
Barriers
- Brand loyalty towards originators.
- Perception of biosimilar efficacy and safety.
- Regulatory and administrative hurdles in some markets.
Forecasts
- Global MS biologics market growth rate: approx. 4.5% annually till 2027.
- Biosimilar uptake expected to capture 30-50% of MS biologic market share in Europe within five years of launch.
- U.S. biosimilar MS segment projected to grow 10-15% annually, driven by market entry of more biosimilars.
Price Projections and Revenue Estimates (2023–2028)
| Year | Market Size (ms patients) | Biosimilar Penetration | Estimated Biosimilar Revenue | Average Price (per patient/year) |
|---|---|---|---|---|
| 2023 | 1.2 million | 5% | $150 million | $50,000 |
| 2024 | 1.3 million | 10% | $260 million | $48,000 |
| 2025 | 1.4 million | 20% | $560 million | $45,000 |
| 2026 | 1.5 million | 30% | $1 billion | $42,000 |
| 2027 | 1.6 million | 40% | $1.3 billion | $40,000 |
| 2028 | 1.7 million | 50% | $1.7 billion | $38,000 |
Assumptions include steady MS prevalence growth and expanding biosimilar adoption.
Impact on the Biosimilar Market and Healthcare Economics
- The entry of REBIF REBIDOSE could lead to a 15% reduction in interferon beta-1a biologic expenditures in the U.S. within three years.
- Competitive pricing may prompt originator firms to lower prices or increase value-added services.
- Broader biosimilar adoption could improve treatment access and adherence.
Key Takeaways
- REBIF REBIDOSE faces a competitive landscape with established originator products and emerging biosimilars.
- Price competition will be aggressive; initial discounts will be around 20-25%, decreasing with market share.
- In Europe, market penetration is expected within two years of approval, with a significant decline in average prices.
- U.S. market entry remains uncertain but could follow similar patterns once approved.
- Biosimilar adoption will significantly influence MS treatment costs, with potential savings of billions annually.
Frequently Asked Questions
1. When is REBIF REBIDOSE expected to launch in major markets?
Market availability depends on regional regulatory approval timelines, with Europe approved in 2021 and the U.S. possibly in 2023.
2. How does REBIF REBIDOSE compare in price to the originator Avonex?
Expected starting prices for REBIF REBIDOSE are roughly 20–25% lower than Avonex. Actual prices depend on payer negotiations.
3. What factors could influence biosimilar adoption rates?
Physician prescribing habits, patient acceptance, regulatory policies, and payer rebate strategies.
4. Will REBIF REBIDOSE completely replace Avonex?
Likely not immediately; brand loyalty and formulary preferences may slow complete substitution.
5. How might price erosion influence biosimilar revenues?
Prices could decline by up to 50% over five years as biosimilars gain share, impacting revenue projections.
References
[1] European Medicines Agency. (2021). EMEA approves biosimilar for multiple sclerosis. EMA.
[2] IQVIA. (2022). Global biologics market size and growth forecast.
[3] FDA. (2022). Biosimilar approval status for MS treatments.
[4] Market Research Future. (2022). Multiple sclerosis drugs: Market analysis and forecasts.
More… ↓
